Business Wire

OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics

OSE is advancing an "Immunotherapy 2.0" future by leveraging MAbSilico’s artificial intelligence-powered software solutions and professional services to accelerate and further optimize the development ...
Business Wire

OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia

OSE Immunotherapeutics and the University of Kiel’s research teams demonstrated that using OSE-127 to target IL-7R is an efficient approach for BCP-ALL immunotherapy and may be particularly beneficial ...
Business Insider

OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration with Memorial Sloan Kettering Cancer Center in New YorkFocused on Company’s Cytotoxic Monoclonal ...

NANTES, France, June 12, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173);(Mnémo:OSE) today announced that the Company has entered into a multi-year research collaboration on ...